Pazopanib HCI

Pazopanib is a multi-receptor tyrosine kinase inhibitor. It inhibits multi-target tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR) -1, -2, and -3, platelet-derived growth factor

IUPAC name:

5-[[4-[(2,3-dimethylindazol-6-yl)-methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide;hydrochloride

CAS No.

635702-64-6

Molecular Weight:

474.0 g.mol−1

Molecular Formula:

C21H24ClN7O2S

Granule:

Available - Ready to press

Mechanism Of Action:

Pazopanib is a second-generation multi-targeted tyrosine kinase inhibitor against vascular endothelial growth factor receptor-1, -2, and -3, platelet-derived growth factor receptor-alpha, platelet-derived growth factor receptor-beta, and c-kit. These receptor targets are part of the angiogenesis pathway that facilitates the formation of tumor blood vessel for tumor survival and growth.

Indication:

First-line treatment of advanced renal cell carcinoma,
Treatment of advanced renal cell carcinoma in patients who have had previous treatment with cytokine therapy.
Treatment of adult patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

information

Category: Oncology

January 21, 2024

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1

DABRAFENIB MESYLATE

Oncology

Cas No: 1195768-06-9

Mechanism Of Action: Dabrafenib is recognized as a competitive and highly selective inhibitor of BRAF. Its mechanism of action involves binding to the ATP pocket

Abemaciclib

Oncology

Cas No: 1231929-97-7

Mechanism Of Action: Abemaciclib demonstrates high selectivity in inhibiting CDK4 and CDK6 with potent activity in the low nanomolar range. By inhibiting the phosphorylation of

Sacubitril-Valsartan

Cardiovascular

Cas No: 936623-90-4

Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and

Roxadustat

Anti-Anemic

Cas No: 808118-40-3

Mechanism Of Action: Anemia is a common complication of chronic kidney disease that can be caused by reduced production of renal erythropoietin (EPO), functional iron